Loma Linda University Cancer Center formed a new Division of Transplant and Cellular Therapy to enhance blood and marrow transplantation and offer novel treatment possibilities, making these options now accessible to patients in the region.
The TCT division will unite pediatric and adult services, providing patients from all walks of life with precise, individualized transplant and therapeutic options, including immune effector, cell and gene therapies, and graft engineering.
Bone marrow transplants, including engineered grafts, along with cell and gene therapy options, will primarily help people diagnosed with cancer. Additionally, people diagnosed with non-malignant genetic conditions will also be able to benefit from the TCT division’s services. Read more.
